These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

850 related articles for article (PubMed ID: 31197598)

  • 1. Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma.
    Dréan A; Lemaire N; Bouchoux G; Goldwirt L; Canney M; Goli L; Bouzidi A; Schmitt C; Guehennec J; Verreault M; Sanson M; Delattre JY; Mokhtari K; Sottilini F; Carpentier A; Idbaih A
    J Neurooncol; 2019 Aug; 144(1):33-41. PubMed ID: 31197598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic efficacy of aldoxorubicin in an intracranial xenograft mouse model of human glioblastoma.
    Marrero L; Wyczechowska D; Musto AE; Wilk A; Vashistha H; Zapata A; Walker C; Velasco-Gonzalez C; Parsons C; Wieland S; Levitt D; Reiss K; Prakash O
    Neoplasia; 2014 Oct; 16(10):874-82. PubMed ID: 25379024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood-brain barrier disruption with low-intensity pulsed ultrasound for the treatment of pediatric brain tumors: a review and perspectives.
    Beccaria K; Canney M; Bouchoux G; Puget S; Grill J; Carpentier A
    Neurosurg Focus; 2020 Jan; 48(1):E10. PubMed ID: 31896084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier.
    Kim M; Ma DJ; Calligaris D; Zhang S; Feathers RW; Vaubel RA; Meaux I; Mladek AC; Parrish KE; Jin F; Barriere C; Debussche L; Watters J; Tian S; Decker PA; Eckel-Passow JE; Kitange GJ; Johnson AJ; Parney IF; Anastasiadis PZ; Agar NYR; Elmquist WF; Sarkaria JN
    Mol Cancer Ther; 2018 Sep; 17(9):1893-1901. PubMed ID: 29970480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma.
    Nepali K; Hsu TI; Hsieh CM; Lo WL; Lai MJ; Hsu KC; Lin TE; Chuang JY; Liou JP
    Eur J Med Chem; 2021 May; 217():113338. PubMed ID: 33744690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced delivery of paclitaxel liposomes using focused ultrasound with microbubbles for treating nude mice bearing intracranial glioblastoma xenografts.
    Shen Y; Pi Z; Yan F; Yeh CK; Zeng X; Diao X; Hu Y; Chen S; Chen X; Zheng H
    Int J Nanomedicine; 2017; 12():5613-5629. PubMed ID: 28848341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment.
    Wang D; Wang C; Wang L; Chen Y
    Drug Deliv; 2019 Dec; 26(1):551-565. PubMed ID: 31928355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier.
    Salphati L; Heffron TP; Alicke B; Nishimura M; Barck K; Carano RA; Cheong J; Edgar KA; Greve J; Kharbanda S; Koeppen H; Lau S; Lee LB; Pang J; Plise EG; Pokorny JL; Reslan HB; Sarkaria JN; Wallin JJ; Zhang X; Gould SE; Olivero AG; Phillips HS
    Clin Cancer Res; 2012 Nov; 18(22):6239-48. PubMed ID: 22992516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood-brain barrier, cytotoxic chemotherapies and glioblastoma.
    Dréan A; Goldwirt L; Verreault M; Canney M; Schmitt C; Guehennec J; Delattre JY; Carpentier A; Idbaih A
    Expert Rev Neurother; 2016 Nov; 16(11):1285-1300. PubMed ID: 27310463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumoral delivery of bortezomib: impact on survival in an intracranial glioma tumor model.
    Wang W; Cho HY; Rosenstein-Sisson R; Marín Ramos NI; Price R; Hurth K; Schönthal AH; Hofman FM; Chen TC
    J Neurosurg; 2018 Mar; 128(3):695-700. PubMed ID: 28409734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
    Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
    Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
    Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trial of blood-brain barrier disruption by pulsed ultrasound.
    Carpentier A; Canney M; Vignot A; Reina V; Beccaria K; Horodyckid C; Karachi C; Leclercq D; Lafon C; Chapelon JY; Capelle L; Cornu P; Sanson M; Hoang-Xuan K; Delattre JY; Idbaih A
    Sci Transl Med; 2016 Jun; 8(343):343re2. PubMed ID: 27306666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of doxorubicin in glioblastoma multiforme following ultrasound-Induced blood-brain barrier disruption as determined by microdialysis.
    Lin YL; Wu MT; Yang FY
    J Pharm Biomed Anal; 2018 Feb; 149():482-487. PubMed ID: 29175555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
    Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
    Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
    Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
    J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles.
    Norouzi M; Yathindranath V; Thliveris JA; Kopec BM; Siahaan TJ; Miller DW
    Sci Rep; 2020 Jul; 10(1):11292. PubMed ID: 32647151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of Thiosemicarbazone Compounds as P-Glycoprotein Inhibitors in Human Primary Brain-Blood Barrier and Glioblastoma Stem Cells.
    Salaroglio IC; Abate C; Rolando B; Battaglia L; Gazzano E; Colombino E; Costamagna C; Annovazzi L; Mellai M; Berardi F; Capucchio MT; Schiffer D; Riganti C
    Mol Pharm; 2019 Aug; 16(8):3361-3373. PubMed ID: 31265310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VEGF-mediated tight junctions pathological fenestration enhances doxorubicin-loaded glycolipid-like nanoparticles traversing BBB for glioblastoma-targeting therapy.
    Wen L; Tan Y; Dai S; Zhu Y; Meng T; Yang X; Liu Y; Liu X; Yuan H; Hu F
    Drug Deliv; 2017 Nov; 24(1):1843-1855. PubMed ID: 29182025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identify a Blood-Brain Barrier Penetrating Drug-TNB using Zebrafish Orthotopic Glioblastoma Xenograft Model.
    Zeng A; Ye T; Cao D; Huang X; Yang Y; Chen X; Xie Y; Yao S; Zhao C
    Sci Rep; 2017 Oct; 7(1):14372. PubMed ID: 29085081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.